Results 121 to 130 of about 16,979 (251)

Impact of RAS/RAF Mutations on Metastatic Treatment Response Following Total Neoadjuvant Therapy in Patients With Stage IV Rectal Cancer

Asia-Pacific Journal of Clinical Oncology, EarlyView.
There is limited understanding of the impact of underlying RAS/RAF mutational status on total neoadjuvant therapy metastatic tumor response rates in curative Stage IV rectal cancer patients. Complete metastatic tumor response to TNT was demonstrated in half as many mRAS as wtRAS patients and disease progression was higher in patients harboring RAS ...
Tracy R. Fitzsimmons, Z. Bunjo, E. L. Neo, A. Badiei, M. Penniment, S. Selva‐Nayagam, A. Ruszkiewicz, J. Wong, T. Sammour   +8 more
wiley   +1 more source

Clinical Characteristics Predict Recurrence in Borderline Ovarian Tumor Patients with Fertility-Preserving Surgery. [PDF]

Int J Gen Med, 2022
He Y, Zhong J, Yang H, Shan N, Cheng A.
europepmc   +1 more source

T Cell Microenvironmental Impacts and Therapeutic Opportunities: Application to Human Testicular Germ Cell Tumors

Andrology, EarlyView.
ABSTRACT Testicular germ cell tumors (TGCT) are the leading malignancy in adolescent and young adult males, yet the immunological and cellular mechanisms governing their tumor microenvironment (TME) remain poorly understood. Here, we present a comprehensive review of TGCT pathobiology with a focus on the immune landscape, particularly the role of tumor‐
R Islam, M Figura, J Heyer, S Lieber, M Huber, KL Loveland, HC Schuppe, Daniela Fietz   +7 more
wiley   +1 more source

Association of recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2, and CHEK2 with the risk of borderline ovarian tumor. [PDF]

Hered Cancer Clin Pract, 2022
Ogrodniczak A, Menkiszak J, Gronwald J, Tomiczek-Szwiec J, Szwiec M, Cybulski C, Dębniak T, Huzarski T, Tołoczko-Grabarek A, Byrski T, Białkowska K, Prajzendanc K, Baszuk P, Lubiński J, Jakubowska A.   +14 more
europepmc   +1 more source

The Functional Role and Molecular Characterization of the Therapeutic Target CLDN6 in Germ Cell Tumors

Andrology, EarlyView.
ABSTRACT Background The tight junction protein CLDN6 has been identified as a cancer‐associated cell surface marker that is rarely expressed in healthy tissues. In testicular germ cell tumors (GCT), CLDN6 is particularly detectable in seminomas, embryonal carcinomas, and choriocarcinomas.
Jule Zwick, Margaretha A. Skowron, Gereon Poschmann, Patrick Petzsch, Ann Kathrin Bergmann, Kai Stühler, Jochen Hecht, Daniel Nettersheim   +7 more
wiley   +1 more source

Bilateral serous surface papillary borderline ovarian tumor with non-invasive implantation: a case report. [PDF]

Front Oncol
Wang Z, Gao S, Wei S, Jiang Y, Li M.
europepmc   +1 more source

Serous Borderline Ovarian Tumor Diagnosis, Management and Fertility Preservation in Young Women. [PDF]

J Clin Med, 2021
Carbonnel M, Layoun L, Poulain M, Tourne M, Murtada R, Grynberg M, Feki A, Ayoubi JM.   +7 more
europepmc   +1 more source

A Spotlight on Yolk‐sac Tumors: Molecular Pathology, Current Diagnostics, and Novel Therapeutics

Andrology, EarlyView.
ABSTRACT Background Yolk‐sac tumors are an aggressive subtype of testicular cancer that significantly contribute to disease progression and therapy resistance, especially in adults. While testicular cancer generally has high cure rates with cisplatin‐based treatment, adult yolk‐sac tumors often appear as components of mixed tumors with poor response to
Evangelos Prokakis, Lisa Schneider, Felix Bremmer, Daniel Nettersheim   +3 more
wiley   +1 more source

The Ultrasonography Characteristics of Borderline Ovarian Tumor Subtypes. [PDF]

J Ultrasound Med
Yoeli-Bik R, Lengyel E, Timor-Tritsch IE, Kurnit K, Puiu S, Longman RE, Abramowicz JS.   +6 more
europepmc   +1 more source

Rapid recurrence of a ruptured mucinous borderline ovarian tumor harboring K-RAS mutation followed by progression into anaplastic carcinoma with TP53 mutation. [PDF]

Heliyon, 2022
Yang Y, Guan Y, Xu M, Liu J.
europepmc   +1 more source